Related Experiment Video

Updated: Jul 15, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Angiogenesis in cancer: molecular mechanisms, clinical impact

M E Eichhorn1, A Kleespies, M K Angele

  • 1Department of Surgery, Klinikum Grosshadern, University of Munich, Marchioninistr. 15, 80337 Munich, Germany.

Langenbeck'S Archives of Surgery
|April 27, 2007
PubMed
Abstract

Insights

Antiangiogenic therapy targets tumor blood vessels, inhibiting cancer growth and metastasis. Combining these therapies with conventional treatments shows promise for multimodal cancer treatment.

Area of Science:

  • Oncology
  • Vascular Biology

Background:

  • Angiogenesis, the formation of new blood vessels, is crucial for tumor growth, progression, and metastasis.
  • Antiangiogenic therapy offers a targeted approach against tumor vasculature, distinct from conventional treatments focusing on tumor cells.

Purpose of the Study:

  • To review molecular mechanisms of tumor angiogenesis.
  • To discuss advances in antiangiogenic drug design.
  • To explore clinical implications of antiangiogenic therapy in surgical oncology.

Main Methods:

  • Literature review summarizing molecular mechanisms of tumor angiogenesis.
  • Discussion of advancements in antiangiogenic drug development.
  • Analysis of clinical applications and outcomes of antiangiogenic therapies.

Main Results:

  • Approved antiangiogenic drugs primarily target vascular endothelial growth factor (VEGF)-mediated angiogenesis.
  • Combination therapies integrating antiangiogenic agents with chemotherapy or radiation are under active clinical investigation.
  • Multimodal approaches aim to simultaneously target tumor cells and their vascular supply.

Conclusions:

  • Antiangiogenic therapy is a promising strategy for cancer treatment.
  • The future clinical potential of antiangiogenic therapy lies in its combination with established standard cancer treatments.

More Related Videos

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...